Technical Data: Examination of the Impact of Microbial μ3D Sample Residue
Microbiome μ3D Auto Scanner: Investigation of the Impact of Sample Residue
This technical document presents the results of verifying the impact of residues in samples on the monitoring of viable cell counts using the Microbio μ3D Auto Scanner. The Microbio μ3D Auto Scanner is a system that continuously monitors the growth of bacteria using the mixed agar plate method, plate spreading, and membrane filter method. While based on culture methods used in official or standard viable cell count tests, it allows for measurement of the number of bacteria in or on the medium much more quickly and accurately than visual counting. [Overview] ■ Purpose ■ Materials and Methods ■ Conclusion ■ Introduction to the Microbio μ3D Auto Scanner For more details, please refer to the catalog or feel free to contact us.
Inquire About This Product
basic information
**Contents** ■Objective - To verify the impact of residues in the sample on the monitoring of viable cell counts using the Microbioμ3D Auto Scanner. ■Materials and Methods - Test strains - Residue samples - Preparation and measurement conditions for residue samples - Measurement results ■Conclusion - It was confirmed that only colonies were accurately detected without mistakenly detecting residues as colonies. ■Introduction to the Microbioμ3D Auto Scanner *For more details, please refer to the catalog or feel free to contact us.*
Price information
Please contact us.
Delivery Time
※Please contact us.
Applications/Examples of results
For more details, please refer to the catalog or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
BD Japan is the Japanese subsidiary of BD, one of the world's leading medical device and medtech companies headquartered in New Jersey, USA. BD aims to lead the world in medical technology, seeking new insights in the healthcare field and improving the quality of diagnosis and treatment, with the purpose of realizing "The future of healthcare for all(TM)." By developing innovative technologies and services related to patient treatment and healthcare processes, BD supports those working on the front lines of healthcare. With approximately 77,000 employees worldwide, BD staff support researchers in the development of next-generation diagnostic and therapeutic methods and strive daily to enhance the safety of healthcare professionals and the efficiency of medical practices in clinical settings. By partnering with healthcare institutions in countries around the world and addressing global priority issues, BD contributes to improving healthcare outcomes, reducing costs, increasing efficiency, enhancing safety, and promoting access to healthcare through close collaboration with its customers, the healthcare institutions.